迈威（上海）生物科技股份有限公司 2025年第二次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 10 月 24 日 证券代码：688062 证券简称：迈威生物 公告编号：2025-063 （二） 股东大会召开的地点：上海市浦东新区李冰路 576 号创想园 3 号楼 103 会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 187 | | --- | --- | | 普通股股东人数 | 187 | | 2、出席会议的股东所持有的表决权数量 | 195,727,595 | | 普通股股东所持有表决权数量 | 195,727,595 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 48.9808 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） ...

北京植德（上海）律师事务所 关于迈威（上海）生物科技股份有限公司 2025 年第二次临时股东大会的 法律意见书 北京植德（上海）律师事务所 关于迈威（上海）生物科技股份有限公司 2025 年第二次临时股东大会的 法律意见书 植德沪（会）字[2025]0045 号 致：迈威（上海）生物科技股份有限公司（贵公司） 北京植德（上海）律师事务所（以下简称"本所"）接受贵公司的委托，指 派律师出席并见证贵公司 2025 年第二次临时股东大会（以下简称"本次会议"）。 植德沪（会）字[2025]0045 号 二〇二五年十月 上海市徐汇区虹桥路 183 号徐家汇中心三期 A 座办公楼 27 层（THREE itc） 邮编：200030 27th Floor Tower A, THREE itc, No.183 Hongqiao Road, Xuhui District, Shanghai 200030 P.R.C 电话(Tel)：021-52533500 传真(Fax)：021-52533599 www.meritsandtree.com （二）本次会议的召开 本所律师参加本次会议进行见证，并根据《中华人民共和国公司法》（ ...

Core Points - The restructuring protein concept declined by 1.15%, ranking among the top declines in concept sectors as of the market close on October 23 [1] - Within the restructuring protein sector, major declines were observed in companies such as Haitai Biological, Maiwei Biological, and Yipinhong, while 14 stocks experienced price increases, with *ST Suwu, *ST Wanfang, and Kefu Medical leading the gains at 5.21%, 4.99%, and 2.90% respectively [1] Market Performance - The top-performing concept sectors today included Shenzhen State-Owned Enterprise Reform with a rise of 6.62%, while the restructuring protein sector faced a decline of 1.15% [2] - The restructuring protein sector saw a net outflow of 476 million yuan, with 37 stocks experiencing net outflows, and 6 stocks seeing outflows exceeding 30 million yuan [2] - Maiwei Biological led the net outflow with 69.48 million yuan, followed by Hualan Biological, BeiDa Pharmaceutical, and Zhifei Biological with outflows of 66.43 million yuan, 54.42 million yuan, and 33.70 million yuan respectively [2] Stock Performance - The top stocks with significant net outflows in the restructuring protein sector included: - Maiwei Biological: -5.53% with a turnover rate of 7.46% and a net outflow of 69.48 million yuan - Hualan Biological: -1.41% with a turnover rate of 1.37% and a net outflow of 66.43 million yuan - BeiDa Pharmaceutical: -3.26% with a turnover rate of 1.78% and a net outflow of 54.42 million yuan [3] - Conversely, the stocks with notable net inflows included: - SanSheng Guojian: +0.67% with a net inflow of 40.98 million yuan - Baipu Sais: +0.17% with a net inflow of 12.23 million yuan - Huiyu Pharmaceutical: +2.96% with a net inflow of 5.71 million yuan [4]

Group 1 - The core point of the news is that Maiwei Biotech's stock price has dropped by 5.29%, currently trading at 42.29 CNY per share, with a total market capitalization of 16.899 billion CNY [1] - Maiwei Biotech, established on May 12, 2017, and listed on January 18, 2022, focuses on the research, production, and sales of therapeutic biological products, with 99.91% of its revenue coming from product sales [1] - The trading volume for Maiwei Biotech reached 128 million CNY, with a turnover rate of 1.46% [1] Group 2 - Huafu Fund has a significant holding in Maiwei Biotech, with its Huafu Health and Entertainment Flexible Allocation Mixed A Fund (001563) holding 170,000 shares, accounting for 6.49% of the fund's net value [2] - The fund has experienced a floating loss of approximately 401,200 CNY today, despite having a year-to-date return of 43.71% [2] - The fund manager, Liao Qingyang, has been in position for nearly 4 years, with the fund's total asset size currently at 74.027 million CNY [2]

迈威（上海）生物科技股份有限公司 证券代码：688062 证券简称：迈威生物 公告编号：2025-062 迈威（上海）生物科技股份有限公司 关于召开 2025 年半年度暨第三季度 业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 说明会类型 迈威（上海）生物科技股份有限公司（以下简称"公司"）已于 2025 年 8 月 30 日在上海证券交易所网站（www.sse.com.cn）披露了《2025 年半年度报告》 及《2025 年半年度报告摘要》，并拟于 2025 年 10 月 31 日披露《2025 年第三季 度报告》。为便于广大投资者更加全面深入地了解公司经营业绩、发展战略等情 董事长、总经理：刘大涛先生 董事、副总经理、董事会秘书：胡会国先生 副总经理、财务负责人：华俊先生 投资者关系副总监：郑川川先生 （如遇特殊情况，参会人员可能进行调整。） 四、投资者参加方式 投 资 者 可 于 2025 年 10 月 31 日 （ 星 期 五 ） 10:00-11:00 通 过 网 址 http ...

Core Viewpoint - Maiwei Biotech's stock has shown significant volatility and performance, with a notable increase in share price year-to-date, despite recent declines in revenue and profit margins [1][2]. Group 1: Stock Performance - As of October 21, Maiwei Biotech's stock price increased by 2.02%, reaching 45.55 CNY per share, with a trading volume of 239 million CNY and a turnover rate of 2.62%, resulting in a total market capitalization of 18.202 billion CNY [1]. - The stock has appreciated by 125.50% year-to-date, with a 2.54% increase over the last five trading days, a 7.94% decrease over the last 20 days, and a 26.88% increase over the last 60 days [1]. - The company has appeared on the "龙虎榜" (a list of stocks with significant trading activity) five times this year, with the most recent appearance on September 2 [1]. Group 2: Financial Performance - For the first half of 2025, Maiwei Biotech reported a revenue of 101 million CNY, reflecting a year-on-year decrease of 12.43%, while the net profit attributable to shareholders was -551 million CNY, a decline of 23.90% compared to the previous period [2]. - As of June 30, 2025, the number of shareholders increased to 17,900, marking an 11.66% rise, while the average number of circulating shares per person decreased by 10.44% to 11,379 shares [2]. Group 3: Shareholder Composition - As of June 30, 2025, the top ten circulating shareholders included Hong Kong Central Clearing Limited as the third-largest shareholder with 4.7426 million shares, marking a new entry [2]. - Xingshan He Run Mixed A (163406) ranked as the fifth-largest shareholder with 3.39 million shares, also a new entry, while Penghua Medical Technology Stock A (001230) was the sixth-largest with 3.1056 million shares, showing a decrease of 1.173 million shares from the previous period [2]. - Several funds, including HSBC Jintrust Smart Manufacturing Pioneer Stock A (001643) and HSBC Jintrust Research Selected Mixed (014423), have exited the top ten circulating shareholders list [2].

Core Insights - Asset management institutions have shown a decline in enthusiasm for researching listed companies in Q3, with a 24.8% decrease in the number of companies surveyed compared to the previous quarter [1] - In contrast, during Q2, there was a significant increase of 49.31% in the number of companies surveyed as the market experienced a period of stagnation [1] - The focus of asset management institutions remains on technology stocks, with a growing interest in pharmaceutical and medical stocks [2] Group 1: Research Activity - In the first three quarters, insurance asset management companies conducted 7,687 surveys on 5,850 individual stocks, with a majority focused on Shenzhen Main Board and Sci-Tech Innovation Board, accounting for 26.92% and 25.91% respectively [2] - The most active insurance asset management company, Taikang Asset, surveyed 860 companies, focusing primarily on the Shanghai Main Board [2] - Broker asset management companies surveyed 4,216 times, with 3,321 individual stocks, showing a preference for high-growth potential and technology-intensive companies [2][3] Group 2: Sector Preferences - In Q3, the Sci-Tech 50 index rose by 49.02%, significantly outperforming the Shanghai and Shenzhen 300 index, which increased by 17.9% [4] - Insurance asset management companies surveyed 600 companies on the Sci-Tech Innovation Board in Q3, making it the most surveyed sector, followed by the Shenzhen Main Board [4] - The most favored stocks among research institutions in Q3 included Mindray Medical, with 538 institutions conducting surveys, followed by Huichuan Technology and Maiwei Biomedical [5]

证券代码：688062 证券简称：迈威生物 公告编号：2025-061 迈威（上海）生物科技股份有限公司 关于 2025 年度第一期定向科技创新债券发行结果的 公告 本 期 发 行 定 向 科 技 创 新 债 券 的 相 关 文 件 已 在 中 国 货 币 网 （www.chinamoney.com.cn）、上海清算所网站（www.shclearing.com.cn）刊登。 经通过"信用中国"网站（www.creditchina.gov.cn）核查，截至本公告日， 公司不属于失信责任主体。 特此公告。 2025 年 9 月 11 日，公司收到交易商协会出具的《接受注册通知书》（中市 协注〔2025〕PPN310 号），交易商协会决定接受公司科技创新债券注册，注册 基础品种为定向债务融资工具，注册金额为 5 亿元，注册额度自通知书落款之日 起 2 年内有效，在注册有效期内可分期定向发行科技创新债券。 公司 2025 年度第一期定向科技创新债券于 2025 年 10 月 15 日完成发行，募 集资金已于 2025 年 10 月 16 日到账。现将发行结果公告如下： | 债券全称 | 迈威（上海）生物科技股份 有限 ...

Core Insights - The article highlights the active engagement of private equity firms in conducting research on listed companies, with a total of 2712 private equity firms researching 1490 stocks, resulting in 18,500 research instances since the beginning of the second half of the year [1][4]. Group 1: Private Equity Research Activity - The most active private equity firms include Shenzhen Shangcheng Asset Management with 291 research instances and Guangdong Zhengyuan Private Equity with 217 instances, covering 271 and 199 stocks respectively [2][1]. - Other notable firms include Qingli Investment and Pankin Investment, with 143 and 142 research instances respectively, both covering 130 stocks [1][2]. - A total of 45 private equity firms conducted between 50 to 100 research instances during the same period [1]. Group 2: Focus Areas of Research - The TMT (Technology, Media, and Telecommunications) sector is a primary focus, with 384 stocks researched, accounting for 25.77% of the total [4]. - Within the TMT sector, the electronics and computer industries had 207 and 118 stocks researched respectively, while the telecommunications and media sectors had fewer stocks at 38 and 21 [4]. - Other sectors with significant research interest include machinery and pharmaceuticals, with 200 and 179 stocks researched respectively [5]. Group 3: Market Performance - The average increase in the 31 Shenwan primary industry indices since the beginning of the second half of the year is 15.13% [5]. - Specific indices in the TMT sector, such as telecommunications, electronics, and power equipment, have seen increases exceeding 40% [5]. - The machinery and basic chemicals sectors also performed well, with increases of 24.16% and 16.47% respectively [5]. Group 4: Stock Performance - Among the 1490 stocks researched, 558 stocks saw price increases between 0%-20%, while 406 stocks increased between 20%-50%, together making up 64.7% of the total [7]. - A total of 44 stocks experienced price increases exceeding 100%, and 154 stocks increased between 50%-100% [7]. - Five stocks attracted over 100 private equity firms for research, including Maiwei Biotech and Mindray Medical, with respective price increases of 66.97% and 3.14% [8].

10月16日，迈威生物盘中上涨2.18%，截至10:16，报48.25元/股，成交2.26亿元，换手率2.34%，总市值 192.81亿元。 资金流向方面，主力资金净流入781.04万元，特大单买入1292.29万元，占比5.71%，卖出1211.61万元， 占比5.35%；大单买入5781.67万元，占比25.53%，卖出5081.31万元，占比22.44%。 迈威生物所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：AI医药、抗癌药物、抗 癌治癌、创新药、眼科概念等。 截至6月30日，迈威生物股东户数1.79万，较上期增加11.66%；人均流通股11379股，较上期减少 10.44%。2025年1月-6月，迈威生物实现营业收入1.01亿元，同比减少12.43%；归母净利润-5.51亿元， 同比减少23.90%。 机构持仓方面，截止2025年6月30日，迈威生物十大流通股东中，香港中央结算有限公司位居第三大流 通股东，持股474.26万股，为新进股东。兴全合润混合A（163406）位居第五大流通股东，持股339.00 万股，为新进股东。鹏华医药科技股票A（001230）位居第六大流通股东，持股 ...